Cargando…
Antioxidant Properties of Oral Antithrombotic Therapies in Atherosclerotic Disease and Atrial Fibrillation
The thrombosis-related diseases are one of the leading causes of illness and death in the general population, and despite significant improvements in long-term survival due to remarkable advances in pharmacologic therapy, they continue to pose a tremendous burden on healthcare systems. The oxidative...
Autores principales: | Falco, Luigi, Tessitore, Viviana, Ciccarelli, Giovanni, Malvezzi, Marco, D’Andrea, Antonello, Imbalzano, Egidio, Golino, Paolo, Russo, Vincenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294911/ https://www.ncbi.nlm.nih.gov/pubmed/37371915 http://dx.doi.org/10.3390/antiox12061185 |
Ejemplares similares
-
Clinical Outcome of Hospitalized COVID-19 Patients with History of Atrial Fibrillation
por: Russo, Vincenzo, et al.
Publicado: (2022) -
Anti-Inflammatory and Anticancer Effects of Anticoagulant Therapy in Patients with Malignancy
por: Russo, Vincenzo, et al.
Publicado: (2023) -
Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation
por: Carbone, Andreina, et al.
Publicado: (2022) -
Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response
por: Rago, Anna, et al.
Publicado: (2023) -
Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study
por: Russo, Vincenzo, et al.
Publicado: (2019)